Actively Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-04-22
240
Participants Needed
24
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
CONDITIONS
Official Title
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of GA of the macula secondary to AMD
- GA lesions between 2.5 and 12.5 mm2 at screening
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye
- Willing and able to comply with clinic visits and study-related procedures, including required meningococcal and pneumococcal vaccinations
You will not qualify if you...
- GA secondary to causes other than AMD
- Active ocular disease that compromises or confounds visual function
- History of surgery for retinal detachment
- Ocular condition other than GA secondary to AMD
- Use of intravitreal complement inhibitors in study eye
- Hereditary or acquired complement deficiency
- Active viral, bacterial or fungal infection
- Liver injury shown by abnormal liver function tests
- Donating blood
- History of choroidal neovascularization in the study eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
ADARx Clinical Site
Gilbert, Arizona, United States, 85297
Actively Recruiting
2
ADARx Clinical Site
Phoenix, Arizona, United States, 85020
Actively Recruiting
3
ADARx Clinical Site
Beverly Hills, California, United States, 90211
Actively Recruiting
4
ADARx Clinical Site
Huntington Beach, California, United States, 93647
Actively Recruiting
5
ADARx Clinical Site
Poway, California, United States, 92064
Actively Recruiting
6
ADARx Clinical Site
Orlando, Florida, United States, 32806
Actively Recruiting
7
ADARx Clinical Site
Wildwood, Florida, United States, 34785
Actively Recruiting
8
ADARx Clinical Site
Hagerstown, Maryland, United States, 21740
Actively Recruiting
9
ADARx Clinical Site
Reno, Nevada, United States, 89502
Actively Recruiting
10
ADARx Clinical Site
Erie, Pennsylvania, United States, 16505
Actively Recruiting
11
ADARx Clinical Site
Austin, Texas, United States, 78705
Actively Recruiting
12
ADARx Clinical Site
Dallas, Texas, United States, 75231
Actively Recruiting
13
ADARx Clinical Site
McAllen, Texas, United States, 78503
Actively Recruiting
14
ADARx Clinical Site
Round Rock, Texas, United States, 78681
Actively Recruiting
15
ADARx Clinical Site
San Antonio, Texas, United States, 78340
Actively Recruiting
16
ADARx Clinical Site
The Woodlands, Texas, United States, 77384
Actively Recruiting
17
ADARx Clinical Site
St. George, Utah, United States, 84790
Actively Recruiting
18
ADARx Clinical Site
Albury, New South Wales, Australia, 2640
Actively Recruiting
19
ADARx Clinical Site
Hurstville, New South Wales, Australia, 2220
Actively Recruiting
20
ADARx Clinical Site
Parramatta, New South Wales, Australia, 2150
Actively Recruiting
21
ADARx Clinical Site
East Melbourne, Victoria, Australia, 3002
Actively Recruiting
22
ADARx Clinical Site
Rowville, Victoria, Australia, 3178
Actively Recruiting
23
ADARx Clinical Site
Ottawa, Ontario, Canada, K2B 7E9
Actively Recruiting
24
ADARx Clinical Site
Toronto, Ontario, Canada, M8X 2X3
Actively Recruiting
Research Team
N
Nali Castillo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here